SLAMF1 and B-cell chronic lymphocytic leukemia: In past studies, we believed that loss of SLAMF1 expression in CLL modulates genetic pathways regulating chemotaxis and autophagy and that potentially affects drug responses, suggesting that the effects underlie unfavorable clinical outcomes experienced by SLAMF1-low patients (Bologna et al., 2016).